ArticleScientific reports2025
Genomic characterization and probiotic assessment of Bifidobacterium breve JKL2022 with strain-specific CLA-converting properties.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Comprehensive safety evaluation of DW2009, a complex ofToxicology reports · 2026Article
- Complete genome sequence ofMicrobiology resource announcements · 2026Article
- Enterococcus hirae Y-HS Alleviates Ulcerative Colitis by Activating PXR/Nrf2-mediated Metabolic-immune Crosstalk.Probiotics and antimicrobial proteins · 2026Article
- Comparative Genomics Analysis Reveals the Strain-specific Probiotic Potential and Putative Antimicrobial Peptides of Bifidobacterium breve NCIM 5671.Current microbiology · 2026Article
- The Role of Diet in Shaping Gut Microbiota and Its Impact on Host Metabolic Regulation.International journal of molecular sciences · 2026Review
- Clinical Safety and Tolerability ofFood science & nutrition · 2026Article
- Functional characterization and safety evaluation of an airway commensalFrontiers in microbiology · 2026Article
- Growth-independent CLA production by Bifidobacterium breve JKL2022 and the potential transcriptional regulatory role of TetR in linoleic acid isomerase expression.Microbial cell factories · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bifidobacterium breve is a well-recognized probiotic species. B. breve JKL2022, a strain isolated from the feces of healthy infants that exhibits superior conjugated linoleic acid (CLA)-converting activity, was functionally characterized for probiotic safety and applicability through genomic and in vitro analyses. The JKL2022 genome comprises a 2,313,948 bp sequence assembled into a single contig, encoding a total of 1,998 genes. In silico predictive analyses confirmed the absence of virulence factors and acquired resistance genes while verifying its intrinsic antimicrobial resistance profile. Several CAZymes were identified, consistent with the strain's fermentation profile. Additionally, the gene encoding the key enzyme for CLA conversion was identified as a 993-bp lai gene, underscoring the species-level differences in microbial CLA metabolism. The functionality, stress tolerance, and safety of JKL2022 were further confirmed through experimental assessments. JKL2022 exhibited tolerance to acid and bile salts, auto-aggregation, and cell surface hydrophobicity, indicating its potential to survive gastrointestinal transit. Furthermore, JKL2022 exhibited α-glucosidase inhibitory activity and tested negative for starch hydrolysis, hemolysis, and gelatinase activity. The inherent probiotic properties of Bifidobacterium, combined with the strain-specific CLA conversion using growing cells and postbiotic preparations, contribute to the potential health benefits of B. breve JKL2022, as verified in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.